Xencor, Inc. $XNCR Shares Bought by Baker BROS. Advisors LP

Baker BROS. Advisors LP lifted its position in Xencor, Inc. (NASDAQ:XNCR) by 64.4% during the third quarter, Holdings Channel reports. The institutional investor owned 1,102,106 shares of the biopharmaceutical company’s stock after buying an additional 431,675 shares during the quarter. Baker BROS. Advisors LP’s holdings in Xencor were worth $12,928,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Hantz Financial Services Inc. boosted its stake in Xencor by 209.1% during the third quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 2,156 shares in the last quarter. GAMMA Investing LLC raised its position in Xencor by 77.1% in the third quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 1,449 shares in the last quarter. Farther Finance Advisors LLC bought a new stake in Xencor in the third quarter worth about $44,000. Federated Hermes Inc. lifted its holdings in Xencor by 114.3% in the 3rd quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock valued at $46,000 after acquiring an additional 2,105 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its position in shares of Xencor by 85.5% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,260 shares of the biopharmaceutical company’s stock valued at $62,000 after purchasing an additional 2,424 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a research note on Monday, December 29th. Barclays increased their target price on shares of Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a research note on Thursday, February 26th. Wall Street Zen lowered shares of Xencor from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Finally, Truist Financial assumed coverage on Xencor in a report on Monday, November 24th. They issued a “buy” rating and a $29.00 price target on the stock. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $25.00.

Xencor Trading Up 3.4%

Shares of XNCR opened at $12.00 on Friday. The business’s 50-day moving average price is $12.47 and its 200 day moving average price is $13.10. The stock has a market capitalization of $880.08 million, a P/E ratio of -9.68 and a beta of 0.95. Xencor, Inc. has a 1-year low of $6.92 and a 1-year high of $18.69. The company has a current ratio of 6.25, a quick ratio of 6.25 and a debt-to-equity ratio of 0.12.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.55. Xencor had a negative net margin of 73.20% and a negative return on equity of 14.58%. The company had revenue of $28.24 million during the quarter, compared to analyst estimates of $29.97 million. During the same period in the prior year, the firm earned ($0.62) earnings per share. The business’s quarterly revenue was down 46.6% on a year-over-year basis. Analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current year.

Insider Activity

In other news, VP John R. Desjarlais sold 2,502 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $11.02, for a total transaction of $27,572.04. Following the sale, the vice president owned 263,831 shares in the company, valued at $2,907,417.62. The trade was a 0.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Celia Eckert sold 3,244 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $11.25, for a total transaction of $36,495.00. Following the completion of the sale, the senior vice president owned 78,685 shares of the company’s stock, valued at approximately $885,206.25. This trade represents a 3.96% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 231,764 shares of company stock worth $3,450,009 over the last 90 days. 4.76% of the stock is owned by company insiders.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.